ACTRN12619001473156招募中1 期
A Phase 1, Randomized, Three-Arm, Double-Blind, Single-Dose Study To Compare The Pharmacokinetics And Safety Of The Potential Biosimilar NeuLara With Ustekinumab In Healthy Volunteers
euClone Proprietary Limited0 个研究点目标入组 210 人开始时间: 2019年10月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1) Male or female, light smoker or non-smoker, greater than or equal to 18 and less than or equal to 55 years of age, with BMI greater than or equal to 17.0 and less than or equal to 32.0 kg/m2 and body weight greater than or equal to 50.0 kg and less than or equal to 100 kg.
- •2) Healthy as defined by:
- •a) the absence of clinically significant illness and surgery within 4 weeks prior to drug
- •administration.
- •b) the absence of clinically significant history of neurological (including seizures),
- •endocrine, cardiovascular (including unstable angina, heart failure, and myocardial
- •infarction), pulmonary (including chronic obstructive pulmonary disease [COPD]),
- •hematological, immunological, psychiatric, gastrointestinal, renal, hepatic,
- •dermatological (including eczema and allergic dermatitis), and metabolic diseases.
- •c) the absence of clinically significant active or chronic infection.
- •d) values for hematology and for biochemistry tests of blood and urine within the reference
- •ranges or showing no clinically relevant deviations as judged by the Investigator.
- •3) Females of childbearing potential who are sexually active with a non-sterile male partner
- •must be willing to use one of the following acceptable contraceptive methods throughout the study and for at least 105 days after drug administration
- •4) Females of non-childbearing potential defined as post-menopausal and surgically sterile
- •5) Male subjects who are not vasectomized for at least 6 months, and who are sexually active
- •with a female partner of childbearing potential must be willing to use one of
- •the following acceptable contraceptive methods throughout the study until at least 105 days
- •after drug administration
- •6) Male subjects with a pregnant partner must agree to use a condom throughout the study until at least 105 days after drug administration.
- •7) Male subjects must be willing not to donate sperm throughout the study until at least
- •105 days following drug administration.
- •8) Capable of consenting and complying with study requirements and procedures.
排除标准
- •1) Any clinically significant abnormality at physical examination or clinically significant
- •abnormal laboratory test results at screening or Day -1.
- •2) Positive test for HIV, hepatitis B, or hepatitis C found during medical screening.
- •3) Positive pregnancy test at screening or Day -1.
- •4) History of allergic reactions to ustekinumab or other related drugs, or to any excipient in the
- •formulation.
- •5) History of previous exposure to ustekinumab or other anti-IL12/23 molecules for a medical
- •condition or in the context of another clinical research study.
- •6) Clinically significant 12-lead ECG abnormalities or vital sign abnormalities at screening.
- •7) History of significant drug abuse within 1 year prior to screening or positive urine drug
- •8) History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol
- •within 6 months prior to the screening visit
- •9) Participation in a clinical research study involving the administration of an investigational or
- •marketed drug or device within 30 days or 5 half-lives of the previous drug
- •10)Use of medications for the timeframes specified below, with the exception of medications
- •exempted by the Investigator on a case-by-case basis because they are judged unlikely to
- •affect the PK profile of the study drug or subject safety (e.g., topical drug products without
- •significant systemic absorption) and hormonal contraceptives
- •11)Have received a live attenuated vaccine within 1 month prior to screening or plan to receive
- •such vaccination during the study.
- •12)Donation of plasma within 7 days prior to dosing. Donation or loss of blood of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to drug administration.
- •13) Breast-feeding subject.
- •14)History of cancer, including any form of skin cancer, or strong family history of cancer
- •15)History of relevant anaphylactic reactions, drug, or food allergies.
- •16) Self or any first degree relative history with known disturbance of coagulation or blood disorder which would be cause for anemia or excess bleeding Inclusion of subjects with first degree relative history of thalassemia will be at the discretion of the
- •Investigator.
- •17)Any confirmed or suspected immunosuppressive or immunodeficient condition based on
- •medical history, family history, and physical examination.
- •18)History of clinically significant opportunistic infection
- •19)History of serious local infection or systemic infection within 3 months prior to screening.
- •20)History of recurrent infections, including recurring sinus and respiratory infections.
- •21) Presence of fever within 2 weeks prior to drug administration.
- •22)History of active tuberculosis or presence of active or latent tuberculosis, or positive
- •QuantiFERON®-TB test indicating possible tuberculosis infection.
- •23)Have resided or travelled in regions where tuberculosis or mycosis is endemic within
- •1 month prior to screening, or plan to visit such a region during the study.
- •24)Any reason which, in the opinion of the Investigator, would prevent the subject from
- •participating in the study.
研究者
相似试验
进行中（未招募）
1 期
Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers to Evaluate Bioequivalence of LusiNEX and Tocilizumab (EU and US)Elevated liver enzymesneutropeniaInflammatory and Immune System - Rheumatoid arthritisthrombocytopeniaACTRN12618000859280Mycenax Biotech Inc.190
进行中（未招募）
不适用
A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of Diamyd® on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes MellitusEstudio multicéntrico, controlado con placebo, doble ciego, aleatorizado, de tres ramas, de fase III para investigar el impacto de Diamyd® en la progresión de la diabetes en pacientes con diagnóstico reciente de diabetes mellitus tipo 1”Patients for the proposed trial are those with recent onset type 1 diabetes (diagnosed within 3 months at screening).Los pacientes para este estudio son aquellos con inicio reciente de Diabetes Mellitus I (diagnosticada en los 3 meses anteriores al momento de la selección).MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusEUCTR2007-002728-13-ESDiamyd Therapeutics AB320
进行中（未招募）
不适用
A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of Diamyd® on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes MellitusPatients for the proposed trial are those with recent onset type 1 diabetes (diagnosed within 3 months at screening).MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusEUCTR2007-002728-13-GBDiamyd Therapeutics AB320
进行中（未招募）
不适用
A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of Diamyd® on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes MellitusEUCTR2007-002728-13-NLDiamyd Therapeutics AB320
进行中（未招募）
不适用
A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of Diamyd® on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes MellitusPatients for the proposed trial are those with recent onset type 1 diabetes (diagnosed within 3 months at screening).MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusEUCTR2007-002728-13-FRDiamyd Therapeutics AB320